Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fuzuloparib-add-improves-metastatic-prostate-cancer-rpfs-2026a1000ite?src=rss
Author :
Publish date : 2026-06-05 09:13:00
Copyright for syndicated content belongs to the linked Source.
